Marshall Wace’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Marshall Wace’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,012,642	Closed	-$10.2M	–	3504
2022 Q4	$10.2M	Hold	1,012,642	–	–	0.02%	784
2022 Q3	$10.1M	Buy	1,012,642 +95,700	+10%	+$946K	0.02%	879
2022 Q2	$9.08M	Hold	916,942	–	–	0.02%	933
2022 Q1	$9.03M	Hold	916,942	–	–	0.02%	947
2021 Q4	$9.02M	Buy	916,942 +600,918	+190%	+$5.9M	0.02%	932
2021 Q3	$3.08M	Buy	316,024 +216,038	+216%	+$2.09M	0.01%	1245
2021 Q2	$967K	Hold	99,986	–	–	﹤0.01%	1826
2021 Q1	$970K	Buy	+99,986	New	+$968K	﹤0.01%	1681

Marshall Wace's BIOT Position: Q1 2023 in Review

Marshall Wace sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 1,012,642 shares — an estimated $10.2M sold.

Marshall Wace first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $10.2M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Marshall Wace reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Marshall Wace sold 1,012,642 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $10.2M.
Marshall Wace first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Marshall Wace's Biotech Acquisition Company Class A Ordinary Shares position peaked at $10.2M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.